Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. STKE, 30 July 2002
Vol. 2002, Issue 143, p. tw270
[DOI: 10.1126/stke.2002.143.tw270]

EDITORS' CHOICE

Biotechnology Is NF-{kappa}B Patent Too Broad?

News reporter P. Brickley highlights controversy surrounding a patent recently issued to David Baltimore and other researchers associated with the Massachusetts Institute of Technology, the Whitehead Institute for Biomedical Research, and Harvard University. The patent covers therapeutic applications of methods that control signaling through the transcription factor NF-{kappa}B. The patented procedures have been licensed to Ariad Pharmaceuticals, and a copy of the patent is available on Ariad's Web site (www.ariad.com). Researcher Sankar Ghosh and unnamed patent lawyers are quoted in the article expressing concerns that the patent is overly broad and could inhibit even academic research on this key signaling pathway. Ariad sued Eli Lilly and Co. for infringement of the patent within hours of its issuance, but chief executive Harvey Berger indicates that Ariad does not intend to initiate action against academic projects that are not connected to commercial sponsors.

P. Brickley, New patent worries professors. The Scientist 16, 19 (2002). [Online Journal]

Citation: Is NF-{kappa}B Patent Too Broad? Sci. STKE 2002, tw270 (2002).


To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882